Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that also assessed the value of other treatments that are simpler and applicable to all stroke patients. A trial that assessed the value of aspirin and beta-blockers against control in all stroke patients would not cost much more than one restricted to comparing anticoagulants against control in patients with stroke and atrial fibrillation but would provide information of more relevance to the management of patients with stroke in the UK.


Journal article



Publication Date





788 - 792


Administration, Oral, Adrenergic beta-Antagonists, Aged, Anticoagulants, Aspirin, Atrial Fibrillation, Cerebral Hemorrhage, Cerebrovascular Disorders, Coronary Disease, Evaluation Studies as Topic, Female, Humans, Long-Term Care, Recurrence, Research Design, Rheumatic Heart Disease, Risk